The ability to rapidly detect and respond to the intentional release of pathogens and toxins is vital in protecting the health and well-being of New Yorkers. The intentional release of Bacillus anthracis through the US Postal Service in 2001 highlighted the need for improved diagnostics in the field of Biodefense. Research at the Biodefense Laboratory focuses on the development of diagnostics for the detection of biothreat agents using platforms such as real-time PCR and sequencing-based technologies. 

Characterization and identification of biothreat agents is performed through analysis of multiple and varied sample types such as clinical specimens, food, water, powders, and other environmental samples. Often, these samples can be difficult to test and specialized protocols are necessary in order to perform nucleic acid testing. This work includes the development and validation of assays that can detect agents such as C. botulinum neurotoxins, Staphylococcal enterotoxins, Orthopoxviruses, Francisella tularensis, Brucella spp. Bacillus anthracis, Ricin toxin, and Yersinia pestis in different samples types in a multiplex format. Additional interests include the evaluation of biothreat samples. The Biodefense laboratory works with federal agencies such as the CDC and DHS as well as other external groups such as test manufacturers and companies to improve biodefense related diagnostics and rapid testing devices.

Awards and Honors

• Member, National Scientific Advisory Board for Biosecurity (2020)

• Recipient of the 2019 North American Global 3Rs Award from AAALAC International and the IQ Consortium

• 2017 APHL Leadership in Biosafety and Biosecurity Award

• 2014 Thomas E. Maxson Education, Training and Workforce Development Award